Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: FML037
MIFTS: 53

Female Breast Cancer

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Female Breast Cancer

About this section

MalaCards integrated aliases for Female Breast Cancer:

Name: Female Breast Cancer 12 15
Female Breast Carcinoma 12 15 73
Malignant Neoplasm of Female Breast 73
Mammary Carcinoma of Female Breast 12
Carcinoma of Female Breast 12

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050671 DOID:7843
NCIt 50 C2918
Sources

Summaries for Female Breast Cancer

About this section
Disease Ontology : 12 A breast carcinoma that is manifested in the female breast.

MalaCards based summary : Female Breast Cancer, also known as female breast carcinoma, is related to breast carcinoma in situ and breast cancer. An important gene associated with Female Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and thyroid, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

Sources

Related Diseases for Female Breast Cancer

About this section

Diseases related to Female Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 breast carcinoma in situ 28.4 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
2 breast cancer 23.7 AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
3 endometrium carcinoma in situ 10.9 PGR TP53
4 scirrhous adenocarcinoma 10.9 ERBB2 PGR
5 breast apocrine carcinoma 10.9 ERBB2 PGR
6 submandibular gland cancer 10.9 KLK3 TP53
7 female reproductive endometrioid cancer 10.8 PGR TP53
8 breast malignant phyllodes tumor 10.8 PGR TP53
9 tetraploidy 10.8 BRCA2 TP53
10 olfactory groove meningioma 10.8 PGR TP53
11 breast mucoepidermoid carcinoma 10.8 ERBB2 PGR
12 vulvar syringoma 10.8 ESR1 PGR
13 lung leiomyoma 10.8 ESR1 PGR
14 vulvar benign neoplasm 10.8 ESR1 PGR
15 breast metaplastic carcinoma 10.8 ERBB2 PGR
16 trigonitis 10.8 ESR1 PGR
17 intracystic papillary adenoma 10.8 ERBB2 PGR
18 atrophy of prostate 10.8 KLK3 TP53
19 vulvar leiomyoma 10.8 ESR1 PGR
20 progesterone-receptor negative breast cancer 10.8 ERBB2 PGR
21 endometrial clear cell adenocarcinoma 10.8 ESR1 TP53
22 gallbladder squamous cell carcinoma 10.8 ERBB2 TP53
23 gastric papillary adenocarcinoma 10.8 ERBB2 TP53
24 predominantly cortical thymoma 10.8 ESR1 PGR
25 tracheoesophageal fistula with or without esophageal atresia 10.7 BRCA2 PALB2
26 progesterone resistance 10.7 ESR1 PGR
27 cribriform carcinoma 10.7 ESR1 PGR
28 non-proliferative fibrocystic change of the breast 10.7 ERBB2 TP53
29 gastric signet ring cell adenocarcinoma 10.7 ESR1 PGR
30 anterior cranial fossa meningioma 10.7 PGR TP53
31 endometrial mucinous adenocarcinoma 10.7 ESR1 PGR
32 adenoid basal cell carcinoma 10.7 ESR1 PGR
33 bap1 tumor predisposition syndrome 10.7 BRCA2 PALB2
34 pleomorphic adenoma carcinoma 10.7 ERBB2 TP53
35 comedo carcinoma 10.7 ERBB2 ESR1
36 deep angioma 10.7 ESR1 PGR
37 glioma susceptibility 1 10.6 ERBB2 TP53
38 estrogen excess 10.6 ESR1 PGR
39 hereditary site-specific ovarian cancer syndrome 10.6 BRCA1 BRCA2
40 bartholin's duct cyst 10.6 AR TP53
41 intramuscular hemangioma 10.6 ESR1 PGR
42 breast reconstruction 10.6 BRCA1 BRCA2
43 uterine body mixed cancer 10.6 ERBB2 PGR TP53
44 breast squamous cell carcinoma 10.6 ERBB2 PGR TP53
45 microglandular adenosis 10.6 ERBB2 PGR TP53
46 vestibular gland benign neoplasm 10.6 ESR1 PGR TP53
47 bartholin's gland adenoma 10.6 ESR1 PGR TP53
48 oral leukoplakia 10.6 ERBB2 TP53
49 papillary adenocarcinoma 10.6 ERBB2 PGR TP53
50 bartholin's gland benign neoplasm 10.6 ESR1 PGR TP53

Comorbidity relations with Female Breast Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Breast Fibroadenosis
Deficiency Anemia Fat Necrosis of Breast
Hypertension, Essential Hypothyroidism
Mastitis Microglandular Adenosis
Neutropenia

Graphical network of the top 20 diseases related to Female Breast Cancer:



Diseases related to Female Breast Cancer
Sources

Symptoms & Phenotypes for Female Breast Cancer

About this section

GenomeRNAi Phenotypes related to Female Breast Cancer according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.21 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 10.21 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 10.21 PALB2 PGR BRCA1 BRCA2
4 Decreased homologous recombination repair frequency GR00236-A-2 10.21 ATM PALB2 PGR BRCA1 BRCA2
5 Decreased homologous recombination repair frequency GR00236-A-3 10.21 PALB2 BRCA1 BRCA2
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 ATM PALB2 BRCA1 TOP2A TP53 BRCA2
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 ATM PALB2 BRCA1 TOP2A TP53 BRCA2
8 Increased cell death HMECs cells GR00103-A-0 9.55 KLK3 PGR BRCA1 TOP2A TP53
9 Decreased viability after ionizing radiation GR00232-A-2 9.43 ATM BRCA1 BRCA2
10 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 PALB2 BRCA1 TOP2A TP53 BRCA2 ATM
11 Decreased TP53 mRNA expression GR00389-S-5 9.32 ATM TP53

MGI Mouse Phenotypes related to Female Breast Cancer:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 PGR TP53 BRCA1 AR BRCA2 ATM
2 cardiovascular system MP:0005385 10.2 TP53 PGR BRCA1 AR ATM ESR1
3 homeostasis/metabolism MP:0005376 10.2 PHB TOX3 TP53 BRCA1 AR BRCA2
4 cellular MP:0005384 10.19 PGR TP53 BRCA1 AR BRCA2 ATM
5 endocrine/exocrine gland MP:0005379 10.19 PHB TP53 BRCA1 AR BRCA2 ATM
6 growth/size/body region MP:0005378 10.18 PHB TP53 BRCA1 AR BRCA2 ATM
7 embryo MP:0005380 10.16 TP53 BRCA1 AR BRCA2 ATM ERBB2
8 mortality/aging MP:0010768 10.15 PHB TOX3 TP53 BRCA1 AR BRCA2
9 integument MP:0010771 10.13 PHB TP53 AR BRCA2 ATM BRCA1
10 limbs/digits/tail MP:0005371 10.01 TP53 BRCA1 AR BRCA2 ERBB2 PALB2
11 digestive/alimentary MP:0005381 10 TP53 BRCA1 AR BRCA2 ESR1 ERBB2
12 neoplasm MP:0002006 9.91 TP53 BRCA2 ATM BRCA1 AR ERBB2
13 muscle MP:0005369 9.8 PGR TP53 BRCA1 AR ESR1 ERBB2
14 normal MP:0002873 9.76 TP53 PGR BRCA1 AR BRCA2 ESR1
15 reproductive system MP:0005389 9.61 PHB TP53 BRCA1 AR BRCA2 ATM
16 skeleton MP:0005390 9.17 PGR TP53 BRCA1 AR ESR1 ERBB2
Sources

Drugs & Therapeutics for Female Breast Cancer

About this section

Drugs for Female Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 210)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 23214-92-8 31703
3
Epirubicin Approved Phase 4,Phase 3,Phase 1,Phase 2 56420-45-2 41867
4
Fluorouracil Approved Phase 4,Phase 3 51-21-8 3385
5
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
6
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
7
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2 112809-51-5 3902
8
Anastrozole Approved, Investigational Phase 4,Phase 2 120511-73-1 2187
9
Toremifene Approved, Investigational Phase 4,Phase 3 89778-26-7 3005573
10
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 437-38-7 3345
12
Morphine Approved, Investigational Phase 4 57-27-2 5288826
13
Methylene blue Approved, Investigational Phase 4 61-73-4
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
15
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3,Not Applicable 31703
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
20 Anesthetics, General Phase 4,Phase 2,Not Applicable
21 Anesthetics, Inhalation Phase 4,Not Applicable
22 Anesthetics, Intravenous Phase 4,Phase 2,Not Applicable
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
24 Hypnotics and Sedatives Phase 4,Phase 3,Phase 2,Not Applicable
25 Platelet Aggregation Inhibitors Phase 4,Not Applicable
26 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
27 Aromatase Inhibitors Phase 4,Phase 3,Phase 2
28 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
29 Estrogen Antagonists Phase 4,Phase 3,Phase 2
30 Estrogens Phase 4,Phase 3,Phase 2,Not Applicable
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
34 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
36 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Estrogen Receptor Modulators Phase 4,Phase 3
39 Selective Estrogen Receptor Modulators Phase 4,Phase 3
40 Anesthetics, Local Phase 4,Phase 3,Phase 2
41 Adjuvants, Anesthesia Phase 4,Phase 2,Not Applicable
42 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
43 Analgesics, Opioid Phase 4,Phase 2,Not Applicable
44 Narcotics Phase 4,Phase 2,Not Applicable
45 Calcium, Dietary Phase 4,Phase 2,Not Applicable,Early Phase 1
46 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
48 Cyclooxygenase Inhibitors Phase 4,Phase 2
49
Docetaxel Approved, Investigational Phase 3,Phase 2,Early Phase 1 114977-28-5 148124
50
Leuprolide Approved, Investigational Phase 3 53714-56-0 3911 657181

Interventional clinical trials:

(show top 50) (show all 157)
# Name Status NCT ID Phase Drugs
1 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4 liposomal doxorubicin;epirubicin
2 Anesthesia and Circulating Tumor Cells in Breast Cancer Completed NCT02005770 Phase 4 Sevoflurane;Propofol
3 Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Recruiting NCT02089854 Phase 4 Toremifene; Anastrozole
4 PEMF and PEC Blocks in Mastectomy Reconstruction Patients Recruiting NCT03360214 Phase 4 Bupivacaine Hydrochloride
5 Efficacy of Transdermal Fentanyl Patches in Relief of Acute Postoperative Pain After Mastectomy Recruiting NCT03051503 Phase 4 The Transdermal Therapeutic System-Fentanyl (TTS-F)
6 Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Recruiting NCT02982148 Phase 4
7 HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer Not yet recruiting NCT03111615 Phase 4 Aromatase Inhibitors
8 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
9 Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients. Completed NCT03381417 Phase 3 pegcyte;Neulastim
10 Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer Completed NCT02980965 Phase 3 letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel;fluorouracil, epirubicin, cyclophosphamide, docetaxel
11 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
12 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
13 Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer Recruiting NCT03351062 Phase 3 Tamoxifen;Toremifene
14 Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients Recruiting NCT03525990 Phase 3
15 Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate Recruiting NCT02600923 Phase 3 Palbociclib;Letrozole
16 A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer Recruiting NCT03403712 Phase 3 fosnetupitant/ palonosetron;netupitant/palonosetron;dexamethasone
17 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Active, not recruiting NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
18 Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block Not yet recruiting NCT03063073 Phase 3 Dexmedetomidine Injection [Precedex];Bupivacaine
19 Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients Unknown status NCT01168505 Phase 2 ferric hydroxide saccharate
20 Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction Completed NCT01466270 Phase 2 donepezil hydrochloride;Placebo
21 Treatment for Patients Suffering From Anemia Due to Chemotherapy Completed NCT00120692 Phase 2 Darbepoetin Alfa;Recombinant Human Erythropoietin
22 Dose Dense TC + Pegfilgrastim Support for Breast Cancer Completed NCT01671319 Phase 2 docetaxel + cyclophosphamide + pegfilgrastim
23 Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients Completed NCT01204125 Phase 2 paclitaxel;Iniparib (SAR2405550 -BSI-201)
24 Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy Completed NCT01091974 Phase 2 armodafinil;Placebo Comparator
25 Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy Completed NCT02527746 Phase 1, Phase 2 EC regimen
26 The HEALS Project - Health Education and Active Living for Surviving Seniors Completed NCT01305044 Phase 2
27 Immunogenicity and Safety of DCs in Breast Cancer Recruiting NCT03450044 Phase 1, Phase 2
28 Tissue Stresses of Cancer (Force Horizon 2020) Recruiting NCT03238144 Phase 1, Phase 2
29 Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA) Recruiting NCT03065621 Phase 2 Palbociclib
30 Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer Recruiting NCT02942355 Phase 2 anastrozole;Palbociclib
31 Study on Androgen Receptor and Triple Negative Breast Cancer Recruiting NCT03383679 Phase 2 Darolutamide;Capecitabine
32 Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab Recruiting NCT03328026 Phase 1, Phase 2 Low dose cyclophosphamide
33 A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant Recruiting NCT02540330 Phase 2 Fulvestrant
34 Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Recruiting NCT03342417 Phase 2
35 PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery Recruiting NCT03084536 Phase 2 Bupivacaine;Gabapentin;Celecoxib;Acetaminophen;Midazolam;Fentanyl
36 Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer Recruiting NCT03112590 Phase 1, Phase 2 Paclitaxel;Trastuzumab
37 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Recruiting NCT03113825 Phase 2 AVB-620
38 Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer Recruiting NCT03384914 Phase 2
39 Denosumab as an add-on Neoadjuvant Treatment (GeparX) Recruiting NCT02682693 Phase 2 Denosumab;nab-Paclitaxel;Epirubicin;Cyclophosphamide;Carboplatin;Trastuzumab;Pertuzumab
40 Phase II Trial for Large ER-Negative Breast Cancers Active, not recruiting NCT01869192 Phase 2 Epirubicin;Cyclophosphamide;Docetaxel;Capecitabine
41 Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer Active, not recruiting NCT01203839 Phase 2
42 Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine Active, not recruiting NCT01654068 Phase 2
43 Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor Not yet recruiting NCT03518138 Phase 2 Q-122;Placebo
44 Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications Not yet recruiting NCT03518242 Phase 2 Cyclophosphamide;Methotrexate;Capecitabine
45 Effect of Methylphenidate on Cancer-related Cognitive Impairment Not yet recruiting NCT02970500 Phase 2 Methylphenidate HCl 10Mg SR;Placebo Comparator
46 Estrogen for Triple Negative Breast Cancer Terminated NCT01083641 Phase 2 Estradiol
47 Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy Terminated NCT02795572 Phase 2
48 Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery Withdrawn NCT01612910 Phase 2 oral microencapsulated diindolylmethane
49 Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) Recruiting NCT03109080 Phase 1 Olaparib
50 G1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast Cancer Recruiting NCT03455270 Phase 1 G1T48

Search NIH Clinical Center for Female Breast Cancer

Sources

Genetic Tests for Female Breast Cancer

About this section
Sources

Anatomical Context for Female Breast Cancer

About this section

MalaCards organs/tissues related to Female Breast Cancer:

41
Breast, Lymph Node, Thyroid, Bone, Prostate, Testes, Skeletal Muscle
Sources

Publications for Female Breast Cancer

About this section

Articles related to Female Breast Cancer:

(show top 50) (show all 190)
# Title Authors Year
1
Acceptability and satisfaction of Project MOVE: a pragmatic feasibility trial aimed at increasing physical activity in female breast cancer survivors. ( 29409128 )
2018
2
Natural Terpenoids Against Female Breast Cancer: a 5-year Recent Research. ( 29446727 )
2018
3
Survival Comparisons Between Early Male and Female Breast Cancer Patients. ( 29891971 )
2018
4
Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. ( 29098396 )
2018
5
Improving Visualization of Female Breast Cancer Survival Estimates: Analysis Using Interactive Mapping Reports. ( 29724710 )
2018
6
Ambient air emissions of polycyclic aromatic hydrocarbons and female breast cancer incidence in US. ( 29730800 )
2018
7
Urban rural disparity in female breast cancer incidence rate in China and the increasing trend in parallel with socioeconomic development and urbanization in a rural setting. ( 29280294 )
2018
8
Personality risk factors of occurrence of female breast cancer: a case-control study in China. ( 29699414 )
2018
9
Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. ( 29678178 )
2018
10
Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC). ( 29294225 )
2018
11
Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer. ( 29396493 )
2018
12
Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. ( 29804200 )
2018
13
Health-related quality of life of African-American female breast cancer survivors, survivors of other cancers, and those without cancer. ( 29704078 )
2018
14
Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10-year (2006-2015) retrospective hospitalization summary report-based study. ( 29624915 )
2018
15
Comparison of epidemiological features, clinicopathological features, and treatments between premenopausal and postmenopausal female breast cancer patients in western China: a retrospective multicenter study of 15,389 female patients. ( 29673111 )
2018
16
Dachshund 1 is Differentially Expressed Between Male and Female Breast Cancer: A Matched Case-Control Study of Clinical Characteristics and Prognosis. ( 29478945 )
2018
17
A Comparison Between Upper Arm and Chest for Optimal Site of Totally Implanted Venous Access Ports in Patients with Female Breast Cancer. ( 29481918 )
2018
18
Work and Female Breast Cancer: The State of the Evidence, 2002-2017. ( 29658425 )
2018
19
Breast specific functional and symptom analysis in female breast cancer survivors. ( 29893309 )
2018
20
Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy. ( 29660599 )
2018
21
Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project. ( 28223083 )
2017
22
Estimated and Interactively Visualized Female Breast Cancer Incidence Rates in Missouri Senate Districts: 2008-2012. ( 29403576 )
2017
23
BRIP1/FANCJ Mutation Analysis in a Family with History of Male and Female Breast Cancer in India. ( 28382101 )
2017
24
No genetic relationship between TLR2 rs4696480, rs3804100, and rs3804099 gene polymorphisms and female breast cancer in Saudi populations. ( 28490891 )
2017
25
Metastasis and its Related Factors in Female Breast Cancer Patients in Kerman, Iran ( 28669169 )
2017
26
[The coping styles and its relationship with quality of life among 1 968 female breast cancer patients in Shanghai in 2014]. ( 28763916 )
2017
27
Impact of Oncotype DX on chemotherapy assignment: a retrospective single-center study on female breast cancer patients. ( 29135103 )
2017
28
Perceptions of Arab men regarding female breast cancer screening examinations-Findings from a Middle East study. ( 28732040 )
2017
29
Association between SNPs in Long Non-coding RNAs and the Risk of Female Breast Cancer in a Chinese Population. ( 28607590 )
2017
30
Province Disparity on Female Breast Cancer in Iran. ( 29259957 )
2017
31
Physical symptoms and working performance in female breast cancer survivors: a systematic review. ( 28325132 )
2017
32
Marital adjustment in the context of female breast cancer: A systematic review. ( 28342270 )
2017
33
Model-based Recursive Partitioning for Survival of Iranian Female Breast Cancer Patients: Comparing with Parametric Survival Models. ( 28451527 )
2017
34
Exploring neighborhood inequality in female breast cancer incidence in Tehran using Bayesian spatial models and a spatial scan statistic. ( 28774168 )
2017
35
No Evaluation of Serum P53 Levels in Iraqi Female Breast Cancer Patients ( 28952299 )
2017
36
Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients. ( 29183284 )
2017
37
Familial associations of female breast cancer with other cancers. ( 28801919 )
2017
38
Predictors of quality of life in Czech female breast cancer survivors following treatment with special interest to coping strategies. ( 28840734 )
2017
39
Clinical outcomes of female breast cancer according to BRCA mutation status. ( 28601786 )
2017
40
Depressive symptoms during adverse economic and political circumstances: A comparative study on Greek female breast cancer patients receiving chemotherapy treatment. ( 28398649 )
2017
41
Male breast cancer: a nation-wide population-based comparison with female breast cancer. ( 29276849 )
2017
42
Geographic variations in female breast cancer incidence in relation to ambient air emissions of polycyclic aromatic hydrocarbons. ( 28616736 )
2017
43
Evaluation of BRCA1 Large Genomic Rearrangements in Group of Egyptian Female Breast Cancer Patients Using MLPA. ( 29019333 )
2017
44
Overview of female breast cancer in northern Tocantins - Brazil. ( 29019533 )
2017
45
Predictors of distress in female breast cancer survivors: a systematic review. ( 28553684 )
2017
46
Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC). ( 29139040 )
2017
47
Descriptive Epidemiology of Female Breast Cancer in Delhi, India ( 28545200 )
2017
48
Dietary Factors and Female Breast Cancer Risk: A Prospective Cohort Study. ( 29215604 )
2017
49
Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens. ( 28639031 )
2017
50
Trends in Female Breast Cancer by Age Group in the Chiang Mai Population ( 28612595 )
2017
Sources

Variations for Female Breast Cancer

About this section
Sources

Expression for Female Breast Cancer

About this section
Search GEO for disease gene expression data for Female Breast Cancer.
Sources

Pathways for Female Breast Cancer

About this section

Pathways related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.73 AR BRCA2 ERBB2 KLK3 TP53
2
Pathways in cancer 37
12.68 AR BRCA2 ERBB2 ESR1 KLK3 TP53
3
Chks in Checkpoint Regulation 64
Show member pathways
 12.56 ATM BRCA1 BRCA2 ESR1 TP53
4
Glioma 37
Show member pathways
 12.55 ATM BRCA1 BRCA2 ERBB2 ESR1 TP53
5
Gastric cancer 37
Show member pathways
 12.51 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
6
MicroRNAs in cancer 37
12.39 ATM BRCA1 ERBB2 TP53
7
Homologous DNA Pairing and Strand Exchange 66
Show member pathways
 12.17 ATM BRCA1 BRCA2 PALB2
8
DNA Damage 4
12.1 ATM BRCA1 BRCA2 PHB TOP2A TP53
9
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) 66
Show member pathways
 12.01 ATM BRCA1 BRCA2 PALB2
10
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 11.98 AR ERBB2 KLK3
11
DNA Damage Response (only ATM dependent) 1
11.87 ATM ERBB2 TP53
12
Signaling by ERBB4 66
Show member pathways
 11.84 ERBB2 ESR1 PGR
13
Fanconi anemia pathway 66 37
11.77 BRCA1 BRCA2 PALB2
14
Androgen receptor signaling pathway 1
11.74 AR BRCA1 KLK3
15
Nuclear Receptor transcription pathway 66
Show member pathways
 11.73 AR ESR1 PGR
16
ATM Pathway 64
Show member pathways
 11.71 ATM BRCA1 TP53
17
BRCA1 Pathway 64
Show member pathways
 11.65 ATM BRCA1 BRCA2 TP53
18
Coregulation of Androgen receptor activity 1
11.51 AR BRCA1 KLK3
19
Pathways Affected in Adenoid Cystic Carcinoma 1
11.44 ATM BRCA1 ERBB2 TP53
20
Integrated Cancer Pathway 1
11.39 ATM BRCA1 TP53
21
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.36 ATM BRCA1 TP53
22
Integrated Breast Cancer Pathway 1
11.35 AR ATM BRCA1 BRCA2 ESR1 PHB
23
FOXA1 transcription factor network 1
Show member pathways
 11.22 AR BRCA1 ESR1 KLK3
24
Platinum drug resistance 37
11.22 ATM BRCA1 ERBB2 TOP2A TP53
25
GADD45 Pathway 64
11.19 ATM BRCA1 TP53
26
BARD1 signaling events 1
11.13 ATM BRCA1 TP53
27
TP53 Network 1
Show member pathways
 10.98 ATM TP53
28
DNA Damage Induced 14-3-3Sigma Signaling 64
10.91 ATM BRCA1 TP53
29
Estrogen Receptor Pathway 1
10.74 CYP1A1 ESR1
Sources

GO Terms for Female Breast Cancer

About this section

Cellular components related to Female Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.85 AR ATM BRCA1 BRCA2 ESR1 PALB2
2 nucleus GO:0005634 9.77 AR ATM BRCA1 BRCA2 ERBB2 ESR1
3 lateral element GO:0000800 9.26 BRCA1 BRCA2
4 protein-containing complex GO:0032991 9.17 AR BRCA1 BRCA2 ESR1 KLK3 TOP2A
5 cytoplasm GO:0005737 10.06 AR ATM BRCA1 BRCA2 CYP1A1 ERBB2

Biological processes related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 DNA repair GO:0006281 9.94 ATM BRCA1 BRCA2 PALB2
2 positive regulation of gene expression GO:0010628 9.88 AR BRCA1 ERBB2 PHB TP53
3 cellular response to DNA damage stimulus GO:0006974 9.88 ATM BRCA1 BRCA2 PALB2 TOP2A TP53
4 protein deubiquitination GO:0016579 9.87 AR BRCA1 ESR1 TP53
5 cell proliferation GO:0008283 9.85 AR BRCA2 CYP1A1 ERBB2 TP53
6 regulation of signal transduction by p53 class mediator GO:1901796 9.82 ATM BRCA1 TP53
7 positive regulation of transcription, DNA-templated GO:0045893 9.8 AR BRCA1 BRCA2 ESR1 PHB TOX3
8 DNA recombination GO:0006310 9.79 BRCA1 BRCA2 PALB2
9 multicellular organism growth GO:0035264 9.73 AR ATM PALB2
10 steroid hormone mediated signaling pathway GO:0043401 9.71 AR ESR1 PGR
11 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.7 ATM BRCA1 BRCA2
12 double-strand break repair via homologous recombination GO:0000724 9.67 ATM BRCA1 BRCA2 PALB2
13 response to X-ray GO:0010165 9.65 BRCA2 TP53
14 mammary gland alveolus development GO:0060749 9.63 AR ESR1
15 DNA double-strand break processing GO:0000729 9.63 ATM BRCA1
16 regulation of apoptotic process GO:0042981 9.63 ATM BRCA1 ESR1 PHB TOX3 TP53
17 regulation of systemic arterial blood pressure GO:0003073 9.62 AR KLK3
18 replicative senescence GO:0090399 9.61 ATM TP53
19 determination of adult lifespan GO:0008340 9.61 ATM TP53
20 inner cell mass cell proliferation GO:0001833 9.6 BRCA2 PALB2
21 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.59 ESR1 TP53
22 positive regulation of transcription by RNA polymerase III GO:0045945 9.58 AR ERBB2
23 progesterone receptor signaling pathway GO:0050847 9.55 PGR PHB
24 chordate embryonic development GO:0043009 9.51 BRCA1 BRCA2
25 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.5 BRCA1 BRCA2 TP53
26 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.43 AR PGR
27 DNA synthesis involved in DNA repair GO:0000731 9.26 ATM BRCA1 BRCA2 PALB2
28 strand displacement GO:0000732 8.92 ATM BRCA1 BRCA2 PALB2
29 regulation of transcription, DNA-templated GO:0006355 10.15 AR BRCA1 BRCA2 ERBB2 ESR1 PGR
30 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 AR BRCA1 ESR1 PGR TOP2A TP53

Molecular functions related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.92 AR BRCA1 ESR1 PGR TP53
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.84 AR ESR1 PGR TP53
3 transcription regulatory region DNA binding GO:0044212 9.78 AR BRCA1 PHB TP53
4 chromatin binding GO:0003682 9.77 AR ESR1 TOP2A TOX3 TP53
5 protein C-terminus binding GO:0008022 9.71 BRCA2 ERBB2 PHB TOP2A
6 histone deacetylase binding GO:0042826 9.69 PHB TOP2A TP53
7 ATPase binding GO:0051117 9.67 AR ESR1 PGR
8 DNA binding GO:0003677 9.65 AR ATM BRCA1 BRCA2 ESR1 PALB2
9 steroid hormone receptor activity GO:0003707 9.63 AR ESR1 PGR
10 nuclear receptor activity GO:0004879 9.43 AR ESR1 PGR
11 steroid binding GO:0005496 9.33 AR ESR1 PGR
12 estrogen response element binding GO:0034056 9.32 ESR1 TOX3
13 enzyme binding GO:0019899 9.23 AR BRCA1 CYP1A1 ESR1 PGR PHB
14 protein binding GO:0005515 10.28 AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
Sources

Sources for Female Breast Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....